Comparison of Aminoven vs Aminoplasmal for Adult Parenteral Nutrition
Both Aminoven and Aminoplasmal are crystalline amino acid solutions suitable for adult parenteral nutrition, with the primary difference being concentration (10% vs 8%) rather than fundamental composition or clinical superiority. The choice between them should be based on the patient's specific protein requirements, fluid restrictions, and electrolyte needs 1.
Key Compositional Differences
Concentration and Protein Delivery
- Aminoven 10%: Delivers 10g amino acids per 100mL (higher concentration)
- Aminoplasmal 8%: Delivers 8g amino acids per 100mL (lower concentration)
This concentration difference means Aminoven provides more protein per unit volume, which is advantageous in fluid-restricted patients (heart failure, renal failure with oliguria) 2.
Electrolyte Content
According to ESPEN guidelines, commercial crystalline amino acid solutions are available with or without pre-added electrolytes 1. The specific electrolyte profiles of each product should guide selection:
- Solutions without electrolytes allow for individualized electrolyte therapy based on patient-specific needs 3
- Solutions with pre-added electrolytes may offer time and cost savings in preparation 4
Clinical Application Framework
Standard Adult Dosing
For metabolically stable adult patients:
- Baseline requirement: 0.8 g/kg/day of amino acids 5
- Increased needs: 1.2-1.5 g/kg/day in catabolic states 6, 5
- Critical illness: Up to 2.0-2.5 g/kg/day in exceptional cases 5
Volume Calculations
- Aminoven 10%: To deliver 1.2 g/kg/day to a 70kg patient requires 840mL
- Aminoplasmal 8%: Same protein delivery requires 1,050mL
Choose Aminoven when fluid restriction is critical; choose Aminoplasmal when higher fluid volumes are tolerated or desired 2.
Metabolic Considerations
Nitrogen-to-Calorie Ratio
Both solutions should be administered with adequate non-protein calories:
- Recommended ratio: 1:130 to 1:170 (g N/kcal) or 1:21 to 1:27 (g AA/kcal) 5
- Each gram of dextrose provides approximately 3.4 kcal 3
Essential Amino Acid Profile
Recent evidence suggests that amino acid composition matters for skeletal muscle mass preservation. Effective PN formulations should provide 7:
- >0.25 g/kg BW total BCAA (branched-chain amino acids)
- ≥0.10 g/kg BW leucine
- ≥0.08 g/kg BW isoleucine
- ≥0.06 g/kg BW methionine
Verify that your chosen solution at the prescribed dose meets these thresholds for muscle mass preservation 7.
Administration Routes
Central Venous Administration
Both solutions are appropriate for central vein administration when combined with concentrated dextrose (typically starting with 10% dextrose, advancing to meet caloric needs) 3.
Peripheral Venous Administration
When diluted to final concentrations of 5-10% amino acids with 5-10% dextrose, both can be administered peripherally 3. However, this provides only 1-1.5 g/kg/day and is intended for short-term nutritional maintenance, not full TPN 3.
Special Population Adjustments
Fluid-Restricted Patients
Aminoven 10% is preferred for patients with:
- Heart failure requiring sodium restriction 2
- Chronic renal failure with oliguria 2
- Any condition requiring concentrated nutrition in lower volumes 2
Patients with High Losses
For patients with gut failure or high-output fistulas requiring supplemental electrolytes, choose the solution without pre-added electrolytes to allow precise electrolyte customization 2.
Stability and Compounding
Both solutions can be used in:
- Three-chamber bags (all-in-one with lipids) 1
- Two-chamber bags (amino acids + glucose only) 1
- Individually compounded admixtures prepared in pharmacy 1
Recent stability data for Aminoplasmal Paed (pediatric formulation) demonstrates 7-day stability at 5±1°C when properly compounded 8, suggesting similar stability profiles exist for adult formulations when stored appropriately.
Critical Pitfalls to Avoid
Never administer amino acids without adequate calories - this wastes protein for gluconeogenesis rather than protein synthesis 5
Monitor serum electrolytes closely regardless of which solution is chosen, as requirements vary significantly between patients 3
Avoid abrupt discontinuation of hypertonic dextrose - taper to 5% dextrose to prevent rebound hypoglycemia 3
Do not use peripheral administration for prolonged periods - insufficient protein delivery leads to continued catabolism 3
Add vitamins and trace elements - omission leads to deficiency complications 1
Bottom Line Decision Algorithm
Choose Aminoven 10% when:
- Fluid restriction is required
- Higher protein delivery per unit volume is needed
- Central venous access is available
Choose Aminoplasmal 8% when:
- Standard fluid volumes are acceptable
- Lower osmolarity is preferred for peripheral administration
- Specific product availability or formulary considerations apply
Both products are clinically equivalent when dosed appropriately to meet protein requirements - the concentration difference is a practical consideration, not a clinical superiority issue 1.